Mednet Logo
HomePediatric Hematology/OncologyQuestion

How would you counsel patients with personal or family histories of autoimmune disease on immune checkpoint inhibitor therapy for Hodgkin lymphoma?

4 Answers
Mednet Member
Mednet Member
Medical Oncology · City of Hope

This is also a tough question. I think patients with autoimmune endocrinopathies (especially Hashimoto’s or Type 1 DM) on stable, longstanding replacement regimens, as well as pre-existing vitiligo, are reasonable candidates for frontline PD-1 based therapies, although they certainly bear very close...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · New York Presbyterian/Weill Cornell Medical Center

In patients with a personal history of active autoimmune disease, I typically recommend treatment with BV and AVD. In young patients, I recommend concomitant BV-AVD, and in older patients, I recommend sequential BV and AVD. In the relapsed/refractory setting, I would cautiously consider using a chec...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Aflac Cancer and Blood Disorders Center/ Children's Healthcare of Atlanta - Egleston

As per the protocol entry criteria for S1826, if a patient themselves has an autoimmune condition, I would not offer them a nivolumab/checkpoint-based regimen. The question of what to do in the setting of a family history: there is no data to answer this accurately- depending on the family history a...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Corewell Health West, Cancer Care and Hematology Sevice Line

Patients with controlled autoimmune conditions or even on low-dose steroids are allowed on AHOD2131, including those on replacement therapy for endocrinopathies. I enrolled a patient on this protocol with controlled IBD (Crohn's), and the patient did well. I offer CPI for patients who meet these cri...

Register or Sign In to see full answer